Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

被引：26
|
作者：
Ciuleanu, T.
Samarzjia, M.
Demidchik, Y.
Beliakouski, V.
Rancic, M.
Bentsion, D. L.
Orlov, S. V.
Schaeffier, B. A.
De Jager, R. L.
Breitz, H. B.
机构：
[1] Inst Oncol I Chiricuta, Cluj Napoca, Romania
[2] Clin Pulm Dis, Zagreb, Croatia
[3] Minsk City Clin Oncol Dispensary, Minsk, BELARUS
[4] Gomel Reg Oncol Dispensary, Gomel, BELARUS
[5] Clin Ctr Nis, Nish, Serbia
[6] Sverdiovsk Reg Oncol Ctr, Ekaterinburg, Russia
[7] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[8] Poniard Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7002
引用
收藏
页数：2
相关论文
共 50 条
  • [41] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    Cappuzzo, F.
    Ciuleanu, T.
    Stelmakh, L.
    Cicenas, S.
    Szczesna, A.
    Juhasz, E.
    Gonzalez, E. Esteban
    Molinier, O.
    Klingelschmitt, G.
    Giaccone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Cang, S.
    Cao, L.
    Chen, E.
    Dong, X.
    Fan, Y.
    Gao, B.
    Guo, Q.
    Huang, D.
    Li, S.
    Liu, A.
    Lv, D.
    Pan, Y.
    Tang, K.
    Yao, W.
    Ye, F.
    Yu, Y.
    Zang, A.
    Gao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S727 - S728
  • [43] A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
    Thomas, S.
    Doebele, R. C.
    Spigel, D.
    Tehfe, M.
    Reck, M.
    Verma, S.
    Zimmermann, A.
    Alexandris, E.
    Lee, P.
    Bonomi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [45] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Brachmann, Rainer Karl
    Zhang, Yuting
    Raponi, Mitch
    Farin, Heinrich
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
    Garcia-Donas, Jesus
    Font, Albert
    Perez-Valderrama, Begona
    Antonio Virizuela, Jose
    Angel Climent, Miquel
    Hernando-Polo, Susana
    Angel Arranz, Jose
    del Mar Llorente, Maria
    Lainez, Nuria
    Carlos Villa-Guzman, Jose
    Mellado, Begona
    Gonzalez del Alba, Aranzazu
    Castellano, Daniel
    Gallardo, Enrique
    Anido, Urbano
    Garcia del Muro, Xavier
    Domenech, Montserrat
    Puente, Javier
    Morales-Barrera, Rafael
    Luis Perez-Gracia, Jose
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (05): : 672 - 681
  • [47] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
    Gupta, Shilpa
    Ballman, Karla V.
    Apolo, Andrea B.
    Sridhar, Srikala S.
    Chen, Ronald C.
    Wen, Yujia
    Yen, Aihua Edward
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Galsky, Matt D.
    Morris, Michael J.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS714 - TPS714
  • [48] A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Raftopoulos, H.
    Laadem, A.
    Puccio, M.
    Knight, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Galsky, Matt D.
    Grande, Enrique
    Davis, Ian D.
    De Santis, Maria
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Mecke, Almut
    Thastrom, Ann Christine
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter L.
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab
    Wilhelm, Francois
    Wilhelm, Isabelle E.
    Azarnia, Nozar
    Maniar, Manoj
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
12345